Open Accessibility Menu

Clinical Trial Information

Expanded Access to Ulixertinib (BVD-523) in Patients with Advanced MAPK Pathway Altered Malignancies
  • Category: Solid Tumors
  • Status: Active
  • Starts: Aug 5, 2025
  • Trial Number: ULI-EAP-100
  • Principal Investigator: Jose Galeas, MD

    Research Nurse: Wendy Blount, RN, MSN

Description of Trial:

The objective of this expanded access program is to provide ulixertinib (BVD-523) for compassionate use in advanced cancer patients with MAPK pathway-altered solid tumor(s), including but not limited to KRAS, NRAS, HRAS, BRAF, MEK, and ERK mutations who have incomplete response to or have exhausted available therapies.

Click here for additional information.